Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Messenger RNA (mRNA) has emerged as an innovative therapeutic modality, offering promising avenues for the prevention and treatment of a variety of diseases. The tremendous success of mRNA vaccines in effectively combatting coronavirus disease 2019 (COVID-19) evidences the unlimited medical and therapeutic potential of mRNA technology. Overcoming challenges related to mRNA stability, immunogenicity, and precision targeting has been made possible by recent advancements in lipid nanoparticles (LNPs). This review summarizes state-of-the-art LNP-mRNA-based therapeutics, including their structure, material compositions, design guidelines, and screening principles. Additionally, we highlight current preclinical and clinical trends in LNP-mRNA therapeutics in a broad range of treatments in ophthalmological conditions, cancer immunotherapy, gene editing, and rare-disease medicine. Particular attention is given to the translation and evolution of LNP-mRNA vaccines into a broader spectrum of therapeutics. We explore concerns in the aspects of inadequate extrahepatic targeting efficacy, elevated doses, safety concerns, and challenges of large-scale production procedures. This discussion may offer insights and perspectives on near- and long-term clinical development prospects for LNP-mRNA therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11185168 | PMC |
| http://dx.doi.org/10.34133/research.0370 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo.
Pharmaceutics
July 2025
Key Laboratory of Colloid and Interface Chemistry of the Ministry of Education, School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, China.
: Lipid nanoparticles (LNPs) represent one of the most effective non-viral vectors for nucleic acid delivery and have demonstrated clinical success in siRNA therapies and mRNA vaccines. While considerable research has focused on optimizing ionizable lipids and helper lipids, the impact of PEGylated lipid content on LNP-mediated mRNA delivery, especially in terms of in vitro transfection efficiency and in vivo performance, remains insufficiently understood. : In this study, LNPs were formulated using a self-synthesized ionizable lipid and varying molar ratios of DMG-PEG2000.
View Article and Find Full Text PDFPre-Vaccination Immune Profiles and Responsiveness to Innate Stimuli Predict Reactogenicity and Antibody Magnitude Following mRNA Vaccination.
Vaccines (Basel)
July 2025
Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD 20814, USA.
Background: While mRNA vaccines effectively limit hospitalization and severe COVID-19 disease, the precise early innate immune mechanisms associated with their efficacy and reactogenicity remain underexplored. The identification of innate immune correlates prior to vaccination could provide mechanistic insights and potentially predict responses.
Methods: We developed an in vitro model to study the innate immune activation of pre-vaccination peripheral blood mononuclear cells (PBMCs) collected from participants enrolled in a well-characterized COVID-19 BioNTech/Pfizer BNT162b2 vaccine (BNT162b2 vaccine) cohort.
Rational design of lipid nanoparticles for enabling gene therapies.
Mol Ther Methods Clin Dev
September 2025
Polymorphic BioSciences Inc, 2665 East Mall, Vancouver, BC V6T 1Z4, Canada.
Lipid nanoparticle (LNP) technology is increasingly enabling RNA-based gene therapies that can potentially be used to treat most diseases. Further, these LNP RNA therapeutics can be designed and manufactured in a matter of weeks, allowing personalized medicines that can be produced in a time frame relevant to individuals suffering from terminal diseases. Here, we focus on the rational design principles that have successfully enabled LNP small interfering RNA (siRNA) formulations to silence pathogenic genes in the liver and LNP mRNA formulations to express therapeutic proteins for vaccines and gene therapies.
View Article and Find Full Text PDFThe kinetics of endosomal disruption reveal differences in lipid nanoparticle induced cellular toxicity.
J Control Release
July 2025
Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, UK.
Lipid nanoparticles (LNPs) are widely used to deliver mRNA therapeutics and vaccines; but treatment-related inflammation can pose safety issues for applications requiring higher doses or repeat administration. The mechanisms underlying the toxicity of LNPs are not fully understood, so improved understanding of the intracellular pathways that sense LNP entry into the cell will facilitate LNP design for successful deployment across different therapeutic applications. Here we explored how experimental conditions can influence the uptake of LNP-delivered mRNA in vitro and modulate both the expression pattern of the cargo and cytotoxicity.
View Article and Find Full Text PDFdemonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape.
RSC Med Chem
June 2025
Department of Chemistry, Graduate School of Science, Nagoya University Furo-cho, Chikusa-ku Nagoya Aichi 464-8602 Japan +81 052 789 2947 +81 052 789 2490.
Current LNP technology faces challenges that must be addressed to enhance the functionality of mRNA therapeutics. Recent studies show disulfide-conjugated molecules improve cell membrane permeability. Here, we investigated incorporating cyclic disulfide (CDL) units into lipid components of LNPs to enhance LNP-mRNA performance.
View Article and Find Full Text PDF